Boryeong Signs Global CDMO Deal With Joulik Pharma To Supply Original Cytotoxic Anti-cancer Drug Alimita To 7 Southeast Asian Countries

Oct 30, 2025

Boryeong Signs Global CDMO Deal With Joulik Pharma To Supply Original Cytotoxic Anti-cancer Drug Alimita To 7 Southeast Asian Countries



Boryeong Co., Ltd. has signed a consignment development production (CDMO) contract with Zuelig Pharma for the supply of the original cytotoxic anticancer drug 'Alimta (component name: Pemetrexed)' in Southeast Asia. Starting in 2027, it will supply Alinta injections to seven Southeast Asian countries, including the Philippines, Thailand, Malaysia, Indonesia, Brunei, Cambodia and Myanmar, with a five-year contract period. The production is carried out through Boryeong Yesan Campus.

Boryeong expects profit growth to begin in earnest from the completion of each country's approval process through this cooperation" he said.

Starting with a contract to supply cytotoxic anticancer drugs with Taiwan Lotus last year, Boryeong signed a contract to supply notifications with Cheflapham and Zyfrexa in July, achieving its strategic goals of improving the quality of profit structure and global transformation of business constitution beyond simple production supply.




As part of its strategy to acquire the original drug business, Boryeong acquired Alimita's domestic rights in 2022 and transformed it into its production system, and has successfully improved its formulation through liquid product launches, strengthening its competitiveness. Boryeong emphasized that "This experience goes beyond simple acquisition and supply, and is a process in which Boryeong has internalized its production and R&D capabilities and increased its business value-added based on the original products it has secured."" Based on these achievements, Boryeong's cooperation with Jules Pharma is an example of Boryeong expanding its global CDMO business, especially its cytotoxic anticancer CDMO business, according to Boryeong.

Cytotoxic anticancer drugs still play a key role in the field of chemotherapy, but in the global market, there are a series of cases of out-of-stock and supply delays due to the production reduction of major pharmaceutical companies. Boryeong is evaluated as a company that can accumulate experience in supplying cytotoxic anticancer drugs such as Gemza and Alimita through the acquisition of the pharmaceutical business and provide a stable and reliable supply chain even amid instability in supply and demand.

Kim Seong-jin, CSO of Boryeong, said "I think this cooperation with Jules Pharma is an important opportunity for Boryeong to expand into a global partnership foundationHe emphasized that "CDMO is particularly meaningful in that it is a business structure that can improve the quality of profits rather than simple external growth.". CSO Kim added that "Boryeong will establish itself as a stable and reliable supplier as a global supply specialist in cytotoxic anticancer drugs based on global-level production infrastructure, quality, and R&D capabilities"."






This article was translated by Naver AI translator.